Article

Double Vision Isn't Unusual in Parkinson's Disease

Author(s):

Though roughly 14 percent of Parkinson's disease patients seen in routine practice have diplopia, most have not discussed it with their physicians, according to a new study presented at the annual meeting of the World Congress of Neurology, held from September 21-26, 2013, in Vienna.

While roughly 14 percent of Parkinson’s disease patients who are seen in routine practice have diplopia, most have not discussed it with their physicians, according to a new study presented at the annual meeting of the World Congress of Neurology, held from September 21-26, 2013, in Vienna.

For their abstract, Anna Sauerbier and colleagues at King’s College of London reviewed data gathered prospectively from Parkinson’s disease patients seen in two neurology clinics. The patient evaluations were conducted with a self-reported Non-Motor Symptoms Questionnaire (NMSQ) and the Non-Motor Symptoms Scale (NMSS), which draws a distinction between diplopia and blurred vision to ensure that the two conditions don’t get confused with one another.

After questioning 257 consecutive patients with Parkinson’s disease, the investigators found that 14.2 percent of the study population, or 35 patients, reported symptoms of diplopia in interviews and self-report questionnaires. The researchers also found that diplopia was significantly correlated with a variety of other non-motor symptoms of the disease.

Among the 35 patients with diplopia, 23 were rated mild, nine were rated moderate, and four were rated severe. Most patients reported that they had not discussed their double vision during their previous visits.

Visual hallucinations were most closely linked with diplopia. Diplopia was also weakly yet significantly associated with patient age and Hoen and Yahr score.

Related Videos
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
© 2024 MJH Life Sciences

All rights reserved.